

# CURRICULUM VITAE

---

## Personal Information

Name: Jonathan Michael HILL  
Email:

## Present Appointments

Consultant Interventional Cardiologist, King's College Hospital  
Director Cardiac Catheterisation Laboratories, King's College Hospital  
Consultant Cardiologist, London Bridge Hospital  
Consultant Cardiologist, King Edward VII Hospital, London

## Education and Training

1979 Royal Grammar School, High Wycombe  
1989 BA (Hons) Pembroke College, Cambridge, Social and Political Science  
1992 MB ChB Edinburgh  
1992-1995 Brompton, St Thomas', Barts, General Medical Training  
1995 London Chest and Barts Cardiology Specialist Training  
1999 - 2003 Cardiovascular Intervention Program NIH/NHLBI USA  
2003 - 2005 Senior Interventional Fellow, London Chest and Barts

## Academic Appointments

1999 - 2003 Visiting Scientist Laboratory of Molecular Biology NHLBI/NIH  
2001 - 2003 Visiting Scientist Cardiovascular Intervention Program NHLBI  
2005 - 2009 Clinical Senior Lecturer, King's College London

## Professional Memberships

1992 GMC Registration 3685576  
1995 MRCP (UK)  
2004 Certificate Completion Specialist Training Cardiology  
2010 FRCP (UK)

## Awards and Honours

1999 Fogarty International Centre, NIH, Bench to Bedside Award  
2003 Outstanding Fellows Award NIH/NHLBI  
2002 American Heart Association Young Clinical Investigator Award Finalist  
2003 American College Cardiology, Young Investigator Award Co Author  
2003 European Society Cardiology, Young Investigator Award Sr Author  
2005 London Interventional Fellows Award  
2015 NIHR Leading Commercial Principal Investigator

## Other Professional Activities

2005-2010	Clinical Governance Lead, King's College Hospital
2007	Level 2 Cardiac CT Training
2009-2011	Programme Committee, Transcatheter Cardiovascular Therapeutics
2010-2015	Training Programme Director, South London Cardiology
2010-2015	Member Specialist Advisory Committee Cardiology
2011	Level 3 Cardiac CT
2011-2013	Cardiovascular Lead, South London Clinical Research Network
2015-2018	Associate Director, Transcatheter Cardiovascular Therapeutics

## Research Training

### *Thesis (PhD Equivalent)*

*"Stem and Progenitor Cells for Vascular Repair and Myocardial Regeneration"*

Bench To Bedside Research Training Fellowship, Laboratory of Molecular Biology,  
Cardiovascular Intervention Programme  
National Heart Lung and Blood Institute  
National Institutes of Health, Bethesda USA  
Supervisors: Arshed Quyyumi, Toren Finkel

### *PhD Supervision*

2001-2005	Jonathan Sorger, Johns Hopkins and Laboratory of Cardiac Energetics, NIH <i>Stem Cell Homing in Myocardial Infarction</i>
2005-2009	Zoe Astroulakis, King's College London <i>Endothelial Progenitor Cells and Cardiac Rehabilitation</i>

### *Thesis Examiner*

2009	Myrielle Mathieu, Universite Libre de Bruxelles <i>Comparison between therapeutic efficiency of bone marrow derived mononuclear and mesenchymal stem cells in chronic myocardial infarction</i>
2012	Margo Klomp, Academic Medical Centre, Amsterdam <i>Endothelial Progenitor Cells and Clinical Trials of Stent Healing</i>
2013	Neil Ruparelia, Balliol College Oxford <i>Monocyte Trafficking in Myocardial Infarction</i>

## Clinical Research Activity

### *Chief Investigator Studies*

Study title:	<b>DISRUPT CAD-3</b>
Condition or Disease:	De novo calcific coronary artery disease
Intervention/Treatment:	Intravascular Lithotripsy
Outline:	IVL for calcified coronary artery disease
Sponsor:	Shockwave Medical
Status:	Recruiting

Study title:	<b>SELECT AMI</b>
Condition or Disease:	Large Myocardial Infarction with persistent RWMA
Intervention/Treatment:	Intracoronary CD 133 cells
Outline:	RCT. CD133 Stem Cell Therapy
Sponsor:	Miltenyi Biotech

Status: Completed

### *Steering Committee*

Study title: **ILUMIEN IV**  
 Condition or Disease: Coronary artery disease  
 Intervention/Treatment: Optical coherence tomography  
 Outline: RCT of OCT vs Angio PCI with Clinical Outcomes  
 Sponsor: Abbott Vascular  
 Status: Recruiting

Study title: **ABSORB UK**  
 Condition or Disease: De Novo lesions  
 Intervention/Treatment: Absorb Bioresorbable Scaffold  
 Outline: BVS for coronary artery disease UK Registry  
 Sponsor: Abbott Vascular  
 Status: Completed

Study title: **CONSISTENT**  
 Condition or Disease: Chronic Total Occlusion  
 Intervention/Treatment: Everolimus eluting biodegradable polymer stent  
 Outline: Subintimal EES BP for CTO with IVUS and OCT assessment  
 Sponsor: Boston Scientific  
 Status: Completed

### *UK Principal Investigator*

Study title: **HEALING IIB**  
 Condition or Disease: De Novo lesions  
 Intervention/Treatment: Genous EPC capture stent  
 Outline: Statin EPC enhancement using Genous "EPC Capture Stent"  
 Sponsor: OrbusNeich  
 Status: Completed

Study title: **BIOMATRIX**  
 Condition or Disease: De Novo Lesions  
 Intervention/Treatment: Biomatrix stent  
 Outline: Registry. Biodegradable stents  
 Sponsor: Biosensors  
 Status: Ongoing

Study title: **IMPRESS**  
 Condition or Disease: PAMI with Cardiogenic "Preshock"  
 Intervention/Treatment: Impella 2.5  
 Outline: Statin EPC enhancement using Genous "EPC Capture Stent"  
 Sponsor: Academic Medical Centre, Amsterdam  
 Status: Completed

Study title: **C-CURE**  
 Condition or Disease: RCT. Cardiopoietic Stem Cell Therapy. Ex vivo culture and transdifferentiation of autologous mesenchymal stem cells and reinjection with NOGA XP  
 Intervention/Treatment: Cardipoeitic stem cell  
 Outline: Transendocardial  
 Sponsor: Cardio3 Biosciences

Status: Completed

Study title: **EUROMAX**  
 Condition or Disease: STEMI/NSTEMI  
 Intervention/Treatment: Bivalirudin  
 Outline: Pan European upstream Bivalirudin administration  
 Sponsor: The Medicines Company  
 Status: Completed

Study title: **ABSORB EXTEND**  
 Condition or Disease: De Novo lesions  
 Intervention/Treatment: Absorb Bioresorbable Scaffold  
 Outline: BVS for coronary artery disease  
 Sponsor: Abbott Vascular  
 Status: Completed

Study title: **ABSORB 2**  
 Condition or Disease: De Novo lesions  
 Intervention/Treatment: Absorb Bioresorbable Scaffold  
 Outline: BVS for coronary artery disease  
 Sponsor: Abbott Vascular  
 Status: Completed

Study title: **SENIOR**  
 Condition or Disease: De novo lesions  
 Intervention/Treatment: Everolimus Eluting stent for patients > 75 years age  
 Outline: PCI for elderly patients with short DAPT  
 Sponsor: Boston Scientific  
 Status: Completed

Study title: **EUROVISION**  
 Condition or Disease: STEMI/NSTEMI  
 Intervention/Treatment: Bivalirudin  
 Outline: PanEuropean bivalirudin use  
 Sponsor: The Medicines Company  
 Status: Completed

Study title: **COSIRA**  
 Condition or Disease: End stage coronary artery disease  
 Intervention/Treatment: Coronary sinus reducer  
 Outline: Refractory myocardial ischaemia treated with CS reducer.  
 Sponsor: Neovasc  
 Status: Completed

Study title: **DISRUPT CAD-1**  
 Condition or Disease: De novo calcific coronary artery disease  
 Intervention/Treatment: Intravascular Lithotripsy  
 Outline: IVL for calcified coronary artery disease  
 Sponsor: Shockwave Medical  
 Status: Completed

Study title: **DISRUPT CAD-2**  
 Condition or Disease: De novo calcific coronary artery disease  
 Intervention/Treatment: Intravascular Lithotripsy  
 Outline: IVL for calcified coronary artery disease  
 Sponsor: Shockwave Medical  
 Status: Data analysis

Study title: **ILUMIEN III**  
 Condition or Disease: Coronary artery disease  
 Intervention/Treatment: Optical coherence tomography  
 Outline: IVUS vs OCT vs Angio for de novo lesions  
 Sponsor: Abbott Vascular  
 Status: Completed

Study title: **CVAD Registry**  
 Condition or Disease: Coronary artery disease and LV dysfunction  
 Intervention/Treatment: Impella CP  
 Outline: Impella CP use for acute and chronic coronary artery disease  
 Sponsor: Abiomed  
 Status: Recruiting

Study title: **REMEDEE-OCT**  
 Condition or Disease: De novo lesion  
 Intervention/Treatment: Genous EPC capture  
 Outline: OCT to assess healing in Genous vs EES  
 Sponsor: Orbus Neich  
 Status: Completed

Study title: **DISRUPT CAD-2**  
 Condition or Disease: De novo calcific coronary artery disease  
 Intervention/Treatment: Intravascular Lithotripsy  
 Outline: IVL for calcified coronary artery disease  
 Sponsor: Shockwave Medical  
 Status: Data analysis

## Publications

### Peer Reviewed

1. Yeoh J, Hill J, Spratt JC. Intravascular lithotripsy assisted chronic total occlusion revascularization with reverse controlled antegrade retrograde tracking. *Catheter Cardiovasc Interv.* 2019 Mar 6. doi: 10.1002/ccd.28165. [Epub ahead of print]
2. Brinton TJ, Ali ZA, Hill JM, Meredith IT, Maehara A, Illindala U, Lansky A, Götberg M, Van Mieghem NM, Whitbourn R, Fajadet J, Di Mario C. Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses. *Circulation.* 2019 Feb 5;139(6):834-836. doi: 10.1161/CIRCULATIONAHA.118.036531. No abstract available.
3. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M, Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M, Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC, Felix SB, Sieweke JT, Møller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW, Henriques JPS, Möbius-Winkler S, Schulze PC, Ouarrak T, Zeymer U, Schneider S, Blankenberg S, Thiele H, Schäfer A, Westermann D. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. *Circulation.* 2019 Mar 5;139(10):1249-1258. doi: 10.1161/CIRCULATIONAHA.118.036614.
4. Danson EJF, Sapontis J, Kaura A, Hill JM, Dworakowski R, MacCarthy P, Melikian N, Webb I, Shah A, Byrne J. Long-term outcomes in surgically ineligible patients managed with percutaneous coronary revascularization or medical therapy. *Cardiovasc Interv Ther.* 2018 Nov 22. doi: 10.1007/s12928-018-0554-5. [Epub ahead of print]
5. Ali ZA, McEntegart M, Hill JM, Spratt JC. Intravascular lithotripsy for treatment of stent underexpansion secondary to severe coronary calcification. *Eur Heart J.* 2018 Nov 19. doi: 10.1093/eurheartj/ehy747. [Epub ahead of print] No abstract available.
6. Jones DA, Rathod KS, Pavlidis AN, Gallagher SM, Astroulakis Z, Lim P, Sirker A, Knight CJ, Dalby MC, Malik IS, Mathur A, Rakhit R, Redwood S, MacCarthy PA, Baker C, Desilva R, Di Mario C, Weerackody R, Hill J, Wragg A, Smith EJ. Outcomes after chronic total occlusion percutaneous coronary interventions: an observational study of 5496 patients from the Pan-London CTO Cohort. *Coron Artery Dis.* 2018 Nov;29(7):557-563. doi: 10.1097/MCA.0000000000000644.
7. Shlofmitz E, Shlofmitz RA, Galougahi KK, Rahim HM, Virmani R, Hill JM, Matsumura M, Mintz GS, Maehara A, Landmesser U, Stone GW, Ali ZA. Algorithmic Approach for Optical Coherence Tomography-Guided Stent Implantation During Percutaneous Coronary Intervention. *Interv Cardiol Clin.* 2018 Jul;7(3):329-344. doi: 10.1016/j.iccl.2018.03.001. Epub 2018 Jun 29. Review.
8. Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, Hill J, Prati F, Colombo A, Di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *EuroIntervention.* 2018 Aug 20;14(6):656-677. doi: 10.4244/EIJY18M06\_01.
9. Katagiri Y, Serruys PW, Macaya C, Ormiston JA, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Wykrzykowska JJ, Piek JJ, Sabaté M, Windecker S, Chevalier B, Onuma Y. The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. *JACC Cardiovasc Interv.* 2018 May 28;11(10):1013-1015. doi: 10.1016/j.jcin.2018.02.020. No abstract available.

10. Walsh SJ, Hanratty CG, Watkins S, Oldroyd KG, Mulvihill NT, Hensey M, Chase A, Smith D, Cruden N, Spratt JC, Mylotte D, Johnson T, **Hill J**, Hussein HM, Bogaerts K, Morice MC, Foley DP. Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study. *EuroIntervention*. 2018 Jun 8;14(3):e318-e324. doi: 10.4244/EIJ-D-18-00346.
11. Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, **Hill J**, Prati F, Colombo A, di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. ESC Scientific Document Group . *Eur Heart J*. 2018 Sep 14;39(35):3281-3300. doi: 10.1093/eurheartj/ehy285.
12. Ali ZA, Karimi Galougahi K, Shlofmitz R, Maehara A, Mintz GS, Abizaid A, Chamié D, **Hill J**, Serruys PW, Onuma Y, Stone GW. Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds. *Expert Rev Cardiovasc Ther*. 2018 Jun;16(6):431-440. doi: 10.1080/14779072.2018.1473034. Epub 2018 May 17. Review.
13. Burzotta F, Nerla R, **Hill J**, Paraggio L, Leone AM, Byrne J, Porto I, Niccoli G, Aurigemma C, Trani C, MacCarthy P, Crea F. Correlation between frequency-domain optical coherence tomography and fractional flow reserve in angiographically-intermediate coronary lesions. *Int J Cardiol*. 2018 Feb 15;253:55-60. doi: 10.1016/j.ijcard.2017.10.011.
14. Roy J, **Hill J**, Spratt JC. The "side-BASE technique": Combined side branch anchor balloon and balloon assisted sub-intimal entry to resolve ambiguous proximal cap chronic total occlusions. *Catheter Cardiovasc Interv*. 2018 Jul;92(1):E15-E19. doi: 10.1002/ccd.27422. Epub 2017 Dec 20.
15. Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, **Hill J**, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. *EuroIntervention*. 2018 Jan 20;13(13):1554-1560. doi: 10.4244/EIJ-D-17-00886.
16. Suna G, Wojakowski W, Lynch M, Barallobre-Barreiro J, Yin X, Mayr U, Baig F, Lu R, Fava M, Hayward R, Molenaar C, White SJ, Roleder T, Milewski KP, Gasior P, Buszman PP, Buszman P, Jahangiri M, Shanahan CM, **Hill J**, Mayr M. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. *Circulation*. 2018 Jan 9;137(2):166-183. doi: 10.1161/CIRCULATIONAHA.116.023381. Epub 2017 Oct 13.
17. Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Böning H, Crea F, Dimmeler S, Dowlut S, Fernández-Avilés F, Galiñanes M, Garcia-Dorado D, Hartikainen J, **Hill J**, Hogardt-Noll A, Homsy C, Janssens S, Kala P, Kastrup J, Martin J, Menasche P, Miklik R, Mozid A, San Román JA, Sanz-Ruiz R, Tendra M, Wojakowski W, Ylä-Herttuala S, Zeiher A. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. *Eur J Heart Fail*. 2017 Nov;19(11):1545-1550. doi: 10.1002/ehf.829. Epub 2017 Sep 25.
18. Ali ZA, Brinton TJ, **Hill JM**, Maehara A, Matsumura M, Karimi Galougahi K, Illindala U, Götberg M, Whitbourn R, Van Mieghem N, Meredith IT, Di Mario C, Fajadet J. Optical Coherence Tomography Characterization of Coronary Lithoplasty for Treatment of Calcified Lesions: First Description. *JACC Cardiovasc Imaging*. 2017 Aug;10(8):897-906. doi:10.1016/j.jcmg.2017.05.012.

19. Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, Baumbach A, Smits P, van Mieghem NM, Bartorelli A, Barragan P, Gershlick A, Kornowski R, Macaya C, Ormiston J, **Hill J**, Lang IM, Egred M, Fajadet J, Lesiak M, Windecker S, Byrne RA, Räber L, van Geuns RJ, Mintz GS, Onuma Y. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. *J Am Coll Cardiol*. 2017 Jul 4;70(1):60-74. doi: 10.1016/j.jacc.2017.05.028.
20. Jaguszewski M, Aloysius R, Wang W, Bezerra HG, **Hill J**, De Winter RJ, Karjalainen PP, Verheye S, Wijns W, Lüscher TF, Joner M, Costa M, Landmesser U. The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis. *JACC Cardiovasc Interv*. 2017 Mar 13;10(5):489-499. doi: 10.1016/j.jcin.2016.11.040.
21. De Silva K, Roy J, Webb I, Dworakowski R, Melikian N, Byrne J, MacCarthy P, **Hill J**. A Calcific, Undilatable Stenosis: Lithoplasty, a New Tool in the Box? *JACC Cardiovasc Interv*. 2017 Feb 13;10(3):304-306. doi: 10.1016/j.jcin.2016.11.048. No abstract available.
22. O'Gallagher K, Nerla R, **Hill J**, Byrne J. Acquired coronary artery aneurysm following treatment with bioresorbable vascular scaffolds. *EuroIntervention*. 2016 Oct 20;12(9):1174. doi: 10.4244/EIJV12I9A189. No abstract available.
23. Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, Ormiston JA, **Hill J**, Lang IM, Egred M, Fajadet J, Lesiak M, Tijssen JG, Wykrzykowska JJ, de Winter RJ, Chevalier B, Serruys PW, Onuma Y. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. *JACC Cardiovasc Interv*. 2016 Jun 27;9(12):1231-42. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.
24. Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, **Hill J**, Hystad M, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. *Eur J Heart Fail*. 2016 Feb;18(2):133-41. doi: 10.1002/ejhf.422. Epub 2015 Oct 16.
25. Urban P, Valdés M, Menown I, Eberli F, Alhaddad I, Hildick-Smith D, Iosseliani D, Roffi M, Oldroyd K, Kalloudi E, Eerdmans P, Berland J, Kleber FX; e-Biomatrix investigators. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry. *Catheter Cardiovasc Interv*. 2015 Dec 1;86(7):1151-60. doi: 10.1002/ccd.25892. Epub 2015
26. George S, Cockburn J, Clayton TC, Ludman P, Cotton J, Spratt J, Redwood S, de Belder M, de Belder A, **Hill J**, Hoyer A, Palmer N, Rathore S, Gershlick A, Di Mario C, Hildick-Smith D. Reply: Long-term follow-up of elective chronic total coronary occlusion angioplasty. *J Am Coll Cardiol*. 2014 Dec 23;64(24):2709-2710. doi: 10.1016/j.jacc.2014.10.004.
27. Verheye S, Jolicœur EM, Behan MW, Pettersson T, Sainsbury P, **Hill J**, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. *N Engl J Med*. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556.
28. George S, Cockburn J, Clayton TC, Ludman P, Cotton J, Spratt J, Redwood S, de Belder M, de Belder A, **Hill J**, Hoyer A, Palmer N, Rathore S, Gershlick A, Di Mario C, Hildick-Smith D; British Cardiovascular Intervention Society; National Institute for Cardiovascular Outcomes Research. Long-term follow-up of elective chronic total



- coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database. *J Am Coll Cardiol*. 2014 Jul 22;64(3):235-43. doi: 10.1016/j.jacc.2014.04.040. Erratum in: *J Am Coll Cardiol*. 2014 Oct 7;64(14):1538.
29. Hamon M, Nienaber CA, Galli S, Huber K, Lipiecki J, **Hill JM**, Amabile N, Bernstein D, Deliargyris E, Lafont A, Steg PG. Bivalirudin in percutaneous coronary intervention: the EUROpean BiVallrudin UtiliSatIOn in Practice (EUROVISION) Registry. *Int J Cardiol*. 2014 May 1;173(2):290-4. doi: 10.1016/j.ijcard.2014.03.003. Epub 2014 Mar 11
  30. O'Gallagher K, Nerla R, **Hill J**, Byrne J.. Acquired coronary artery aneurysm following treatment with bioresorbable vascular scaffolds. *EuroIntervention*. 2016 Oct 20;12(9):1174. doi: 10.4244/EIJV12I9A189. PubMed PMID: 27753602.
  31. Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, Ormiston JA, **Hill J**, Lang IM, Egred M, Fajadet J, Lesiak M, Tijssen JG, Wykrzykowska JJ, de Winter RJ, Chevalier B, Serruys PW, Onuma Y. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. *JACC Cardiovasc Interv*. 2016 Jun 27;9(12):1231-42. doi: 10.1016/j.jcin.2016.03.027. PubMed PMID: 27262861.
  32. Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, **Hill J**, Hystad M, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. *Eur J Heart Fail*. 2016 Feb;18(2):133-41. doi: 10.1002/ejhf.422. PubMed PMID: 26470631.
  33. Urban P, Valdés M, Menown I, Eberli F, Alhaddad I, Hildick-Smith D, Iosseliani D, Roffi M, Oldroyd K, Kalloudi E, Eerdmans P, Berland J, Kleber FX; e-Biomatrix investigators.. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry. *Catheter Cardiovasc Interv*. 2015 Dec 1;86(7):1151-60. doi: 10.1002/ccd.25892. PubMed PMID: 25683225.  
Co Investigator
  34. Verheye S, Jolicœur EM, Behan MW, Pettersson T, Sainsbury P, **Hill J**, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. *N Engl J Med*. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556. PubMed
  35. George S, Cockburn J, Clayton TC, Ludman P, Cotton J, Spratt J, Redwood S, de Belder M, de Belder A, **Hill J**, Hoyer A, Palmer N, Rathore S, Gershlick A, Di Mario C, Hildick-Smith D. Reply: Long-term follow-up of elective chronic total coronary occlusion angioplasty. *J Am Coll Cardiol*. 2014 Dec 23;64(24):2709-10. doi: 10.1016/j.jacc.2014.10.004. PubMed PMID: 25524352.
  36. Hamon M, Nienaber CA, Galli S, Huber K, Lipiecki J, **Hill JM**, Amabile N, Bernstein D, Deliargyris E, Lafont A, Steg PG. Bivalirudin in percutaneous coronary intervention: the EUROpean BiVallrudin UtiliSatIOn in Practice (EUROVISION) Registry. *Int J Cardiol*. 2014 May 1;173(2):290-4. doi: 10.1016/j.ijcard.2014.03.003. PubMed PMID: 24680250.
  37. Wilson WM, Walsh S, Hanratty C, Strange J, **Hill J**, Sapontis J, Spratt JC. A novel approach to the management of occlusive in-stent restenosis (ISR). *EuroIntervention*. 2014 Mar 20;9(11):1285-93. doi: 10.4244/EIJV9I11A218. PubMed PMID: 24650770.
  38. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI

- Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. *JAMA* 2012 May 2; 307(17):1817-26. doi: 10.1001/jama.2012.421. PubMed PMID: 22447888. (Co Investigator).
39. den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, **Hill J**, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ. Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. *Atherosclerosis*. 2011 Nov;219(1):245-52. doi: 10.1016/j.atherosclerosis. 2011.06.032. PubMed PMID: 21763653.
  40. Bartunek J, Vanderheyden M, **Hill J**, Terzic A. Cells as biologics for cardiac repair in ischaemic heart failure. *Heart*. 2010 May;96(10):792-800. doi: 10.1136/hrt.2007. 139394. Review. PubMed PMID: 20448133.
  41. Sirker AA, Astroulakis ZM, **Hill JM**. Vascular progenitor cells and translational research: the role of endothelial and smooth muscle progenitor cells in endogenous arterial remodelling in the adult. *Clin Sci (Lond)*. 2009 Feb;116(4):283-99. doi: 10.1042/CS20080001. Review. PubMed PMID: 19138170.
  42. Pula G, Mayr U, Evans C, Prokopi M, Vara DS, Yin X, Astroulakis Z, Xiao Q, **Hill J**, Xu Q, Mayr M. Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. *Circ Res*. 2009 Jan 2;104(1):32-40. doi: 10.1161/CIRCRESAHA.108.182261. PubMed PMID: 19023133.
  43. Khurana R, Mayr M, **Hill JM**. Endothelial progenitor cells, late stent thrombosis and delayed re-endothelialisation. *EuroIntervention*. 2008 Jan;3(4):518-25. PubMed PMID: 19736097.
  44. Beeres SL, Bengel FM, Bartunek J, Atsma DE, **Hill JM**, Vanderheyden M, Penicka M, Schalij MJ, Wijns W, Bax JJ. Role of imaging in cardiac stem cell therapy. *J Am Coll Cardiol*. 2007 Mar 20;49(11):1137-48. Review. PubMed PMID: 17367656.
  45. Rajakaruna C, **Hill J**, Turner EJ, Sirker A, Rana BS, Wendler O. A novel surgical approach to close an acute ventricular septal defect using an occlude device. *J Thorac Cardiovasc Surg*. 2007 Feb;133(2):579-80. PubMed PMID: 17258610.
  46. Paul JD, Powell TM, Thompson M, Benjamin M, Rodrigo M, Carlow A, Annavajhala V, Shiva S, Dejam A, Gladwin MT, McCoy JP, Zalos G, Press B, Murphy M, **Hill JM**, Csako G, Waclawiw MA, Cannon RO 3rd. Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation. *J Cardiopulm Rehabil Prev*. 2007 Mar-Apr;27(2):65-73. PubMed PMID:17558240.
  47. **Hill JM**, Bartunek J. The end of granulocyte colony-stimulating factor in acute myocardial infarction? Reaping the benefits beyond cytokine mobilization. *Circulation*. 2006 Apr 25;113(16):1926-8. PubMed PMID: 16636185.
  48. **Hill JM**, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO 3rd. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. *J Am Coll Cardiol*. 2005 Nov 1;46(9):1643-8. PubMed PMID: 16256862; PubMed Central PMCID: PMC1351145.
  49. Powell TM, Paul JD, **Hill JM**, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, Cannon RO 3rd. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery

- disease. *Arterioscler Thromb Vasc Biol.* 2005 Feb;25(2):296-301. PubMed PMID: 15569821.
50. Syed MA, Paterson DI, Ingkanisorn WP, Rhoads KL, **Hill J**, Cannon RO 3rd, Arai AE. Reproducibility and inter-observer variability of dobutamine stress CMR in patients with severe coronary disease: implications for clinical research. *J Cardiovasc Magn Reson.* 2005; 7(5):763-8. PubMed PMID: 16353436.
  51. Shapiro EM, Skrtic S, Sharer K, **Hill JM**, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. *Proc Natl Acad Sci U S A.* 2004 Jul 27;101(30):10901-6. PubMed PMID: 15256592; PubMed Central PMCID: PMC503717.
  52. Dick AJ, Guttman MA, Raman VK, Peters DC, Pessanha BS, **Hill JM**, Smith S, Scott G, McVeigh ER, Lederman RJ. Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in Swine. *Circulation.* 2003 Dec 9;108(23):2899-904. PubMed PMID: 14656911; PubMed Central PMCID: PMC1325104.
  53. **Hill JM**, Dick AJ, Raman VK, Thompson RB, Yu ZX, Hinds KA, Pessanha BS, Guttman MA, Varney TR, Martin BJ, Dunbar CE, McVeigh ER, Lederman RJ. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. *Circulation.* 2003 Aug 26;108(8):1009-14. PubMed PMID: 12912822; PubMed Central PMCID: PMC1490325.
  54. Hinds KA, **Hill JM**, Shapiro EM, Laukkanen MO, Silva AC, Combs CA, Varney TR, Balaban RS, Koretsky AP, Dunbar CE. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. *Blood.* 2003 Aug 1;102(3):867-72. PubMed PMID: 12676779.
  55. **Hill JM**, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med.* 2003 Feb 13;348(7):593-600. PubMed PMID: 12584367.
  56. Stem cells for myocardial regeneration. Orlic D, **Hill JM**, Arai AE. *Circ Res.* 2002 Dec 13;91(12):1092-102. Review. PubMed PMID: 12480809.
  57. Exercise tolerance testing **Hill J**, Timmis A *BMJ.* 2002 May 4;324(7345):1084-7. Review. PubMed PMID: 11991917; PubMed Central PMCID: PMC1123032.

### *Other Publications*

**Book:** Oxford Handbook of Cardiology 1<sup>st</sup> Edition, 2<sup>nd</sup> Edition  
 Ramrakha P and **Hill JM**  
 Oxford University Press  
 3<sup>rd</sup> Edition in preparation  
 Winner of Best Cardiology Book, BMJ Book Awards

Numerous abstracts and multiple book chapters

## Invited Lectures and Meeting Contributions

- | Year | Event/ <b>Contribution</b>  |
|------|---|
| 2003 | Stem Cell Symposium, Frankfurt<br><b>Lecture:</b> Stem Cell Homing in Myocardial Infarction   |
|      | Lifeline Foundation, Research Initiative in Vascular Disease, Bethesda<br><b>Lecture:</b> Endothelial Progenitor Cells and Vascular Function          |
|      | International Society of Cell Therapy, Phoenix<br><b>Lecture:</b> Stem Cells for Myocardial Repair  |
|      | Steering Committee, Icelandic Heart Study, Reykjavik<br><b>Lecture:</b> Endothelial Progenitor Cells  |
| 2004 | British Atherosclerosis Society, Oxford<br><b>Lecture:</b> Circulating Endothelial Progenitor Cells, Vascular Function and Cardiovascular Risk        |
|      | International Society of Cell Therapy, Dublin<br><b>Lecture:</b> Intravenous Allogeneic Mesenchymal Stem Cells for Myocardial Regeneration.           |
|      | Oxford University, Oxford<br><b>Lecture:</b> MRI and Stem Cell Tracking   |
|      | Cardiac Cell Therapy: Present and Future, Kittendorf<br><b>Lecture:</b> Endothelial Progenitor Cells, CV risk & vascular function                     |
|      | British Cardiac Society, Manchester<br><b>Lecture:</b> Use of Stem Cells to predict risk in patients  |
|      | International Society for Blood Transfusion, Edinburgh<br><b>Lecture:</b> Endothelial Progenitor Cells  |
|      | European Society of Cardiology, Munich<br><b>Lecture:</b> Endothelial Rejuvenation by Circulating Progenitor Cells                                    |
|      | TCT, Washington<br><b>Lecture:</b> Autologous Skeletal Myoblasts: Capacity for Myogenesis, Predilection for Side Effects                              |
|      | Imperial College London Heart Science Seminar Harefield Hospital, London<br><b>Lecture:</b> Cardiac Magnetic Resonance Imaging of Injected Stem Cells |
|      | British Heart Foundation Symposium "Stem Cells and the Heart", London<br><b>Lecture:</b> EPCs and MSCs for Vascular and Myocardial Repair             |
| 2005 | Emerging Technologies Symposium, France<br><b>Lecture:</b> Late Breaking Trials from the ACC (Reality, Endeavour II, Taxux V)                         |
|      | Transradial Intervention, London Chest Hospital<br><b>Live Case Operator</b>  |
|      | London Intervention Live, King's College Hospital<br><b>Live Case Operator</b>  |

Baltic Stem Cell Conference, Rostock  
**Lecture:** G-CSF in acute ischaemia? Is it safe?

Glasgow University  
**Lecture:** Stem and Progenitor Cells for Myocardial Infarction

2006 Conference on Cell Therapy for Cardiovascular Disease, New York  
**Lecture:** Clinical Trials for Myocardial Ischemia- Granulocyte Colony Stimulating Factor

Advanced Angioplasty, London  
**Lecture:** Cardiac Regeneration: Fantasy or Fact?

London Ambulance Service, Live Case Day, King's College Hospital  
**Course Director**  
**Live Case Operator**

Emerging Technologies Symposium, Switzerland  
**Course Director**  
**Lecture:** Long Term Drug Eluting Stent Data

London Transradial Intervention Course  
**Live Case Operator**

Third International Symposium on Gene and Stem Cell Therapy, Valladolid  
**Lecture:** Trafficking and Homing of stem cells to repair the cardiovascular system. How to track the destiny of cells after therapeutic intravascular or intramyocardial delivery

International Society of Cell Therapy, Berlin  
**Lecture:** Advancing the Clinical Applications of CD34+ in Cardiovascular Disease

London Intervention Meeting, London  
**Live Case Operator**

Vascular Biology Forum, NHLI, Imperial College  
**Lecture:** Endothelial Progenitor Cells and Cardiovascular Disease

Transcatheter Cardiovascular Therapeutics, Washington  
**Lecture:** Cell Therapy and Myocardial Repair: Cell Tracking

Symposium, Shanghai Stem Cell Mission to UK, London  
**Lecture:** Cardiovascular Stem Cells

King's Stem Cell Symposium, London  
**Lecture:** Proposed Clinical Trial in acute MI

Tokyo Women's Medical University, Tokyo  
**Lecture:** Trafficking and Homing of Stem Cells for Myocardial Regeneration; Methods for cell tracking

Establishing a Primary PCI Service in AMI, Cambridge  
**Lecture:** How to maximise early diagnosis

Primary PCI Live London, London  
**Course Director**  
**Live Case Operator**

- 2007 International Conference on Cell Therapy for Cardiovascular Disease, New York  
**Course Co Director**  
**Lecture:** Cell Tracking and Retention, Techniques and Relevance
- Advanced Angioplasty, London  
**Lecture:** Contemporary Trials
- London Ambulance Service, Live Case Day, King's College Hospital  
**Course Director**  
**Live Case Operator**
- London Regenerative Medicine Network, London  
**Lecture:** Stem and Progenitor Cells for Myocardial Regeneration
- British Cardiac Society, Glasgow  
**Lecture:** Endothelial Progenitor Cells
- Autologous Stem Cells in Cardiovascular Disease, Bristol  
**Lecture:** EPCs and Cardiovascular Risk
- TOPIC: Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo  
**Lecture:** EPCs in Health and Disease
- ENCORE SEOUL: Endovascular and Coronary Revascularisation, Seoul  
**Lecture:** Stem Cell Tracking
- Cardiac Cell Therapy Innovation Symposium, Copenhagen  
**Lecture:** Stem Cell Trafficking and Homing to Repair the Cardiovascular System.  
 How to track the destiny of cells after therapeutic intravascular or intramyocardial delivery
- TCT, Washington  
**Lecture:** Emerging Clinical Relevance of De Novo EPC Levels  
 Live Case Operator
- 2008 International Conference on Cell Therapy for Cardiovascular Diseases, New York  
**Co-Director**
- Singapore Live  
**Lecture:** CD34 Cell Capture and Concept of Endothelisation after Stenting
- Royal Society of Medicine Interventional Training Day, London  
**Lecture:** Stem Cells: The future for interventional cardiology or just another pipe dream?
- EuroPCR, Barcelona  
**Lecture:** Optical Coherence Tomography results from biodegradable polymers
- National Congress of Cardiovascular Medicine, Iran  
**Lecture:** Next Generation Stents; Polymer Technology and Clinical Benefits
- Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo  
**Lecture:** Endothelial Progenitor Cells functional importance for accelerated natural healing
- CTO Workshop and Training Day King's College Hospital, London  
**Live Case Proctoring**
- Stem Cell Meeting, Lugano  
**Lecture:** Trafficking and Homing of Stem Cells to repair the cardiovascular system

ENCORE SEOUL Endovascular and Coronary Revascularisation, Seoul

**Lecture:** Stem Cell Tracking

Transcatheter Cardiovascular Therapeutics, Washington

**Lecture:** CD133 Cells for STEMI: SELECT AMI

**Lecture:** Endothelial Progenitor Cell Function is a Key Variable in Clinical Outcomes

Chronic Total Occlusions 5, Leicester

**Faculty**

European Cardiovascular Experts Summit: STEMI, Zurich

**Chair**

**Lecture:** Switching or Stacking Anti Thrombin in STEMI and High Risk ACS.

European Interventional Fellows Course, London

**Lecture:** Cell Therapy and Basic Science for the Interventionist

National Infarct Angioplasty Project, London

**Chair**

2009 The International Conference on Cell Therapy for Cardiovascular Diseases, New York

**Co Director**

British Heart Foundation Workshop: Cardiac Stem Cells and Repair, London

**Steering Committee Member**

Drug Eluting Stent Symposium, Dubai

**Lecture:** Polymer Technology and Clinical Benefits

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Stent Rendothelialisation

**Lecture:** Cypher Drug Eluting Stent

TCT ,San Francisco

**Faculty**

Medical Directors' Conference SHA Showcase London

**Lecture:** Primary Angioplasty in London

European Interventional Cardiology Fellows Course, London

**Lecture:** CTO Illustrative Case Review

Polymer Scientific Summit, New York

**Chair**

2010 American College of Cardiology i2 Summit, Atlanta

**Chair:** Complex Coronary Patient: End Stage Patient

Belgrade Summit of Interventional Cardiology, Serbia

**Lecture:** Endothelial Progenitor Cells and Stent Healing

BALTICs Interventional Meeting, Latvia

**Lecture:** EPCs in Health and Disease

EuroPCR Paris

**Faculty**

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Are DES associated with late catch up phenomenon

**Lecture:** When not to do CTOs

TCT, Washington

**Faculty**

CTO 7, Leicester

**Faculty**

New York Polymer Scientific Summit

**Chair**

Interventional Summit, Bakulev Institute, Moscow

**Lecture:** Stent Healing with Biodegradable Polymers

2011 International Conference on Cell Therapy for Cardiovascular Disease, New York  
**Course Co Director**

Advanced Cardiovascular Intervention, London

**Lecture:** The Ideal Scaffold -Properties and Kinetics

Beyond the Angiogram, Bristol

**Faculty**

Beyond the Angiogram, Edinburgh

**Lecture:** OCT Clinical Applications

EuroPCR, Paris

**Lecture:** Which patients are not candidates for dual antiplatelet therapy? What are alternative treatment options for such patients?

6<sup>th</sup> European Meeting for Vascular Biology and Medicine, Krakow

**Lecture:** EPCs, OCT and Vascular Repair

Advanced Intracoronary Diagnostics: Beyond the Angiogram 2, London

**Course Director**

CTO 8, Leicester

**Faculty**

2012 Advanced Cardiovascular Intervention, London

**Lecture:** Should bioabsorbable polymers and absorbable scaffolds make a difference

German Society of Cardiology, Mannheim

**Lecture:** Absorb: The Fourth Revolution

Beyond the Angiogram 3, Edinburgh

**Lecture:** Clinical Applications of OCT

EuroPCR, Paris

**Faculty**

HeartLive, Manchester

**Faculty**

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** The Next Era "Combo" Dual Therapy Stent

**Lecture:** Case Review of Left Main Stem Stenting



Essex Cardiology Meeting, Chelmsford

**Lecture:** Coronary Imaging with Optical Coherence Tomography

TCT, Miami

**Lecture:** Assessing EPC Capture Effects on Vascular Healing

CTO9, Leicester

**Faculty**

2013 Advance Cardiovascular Intervention, London

**Faculty**

Portuguese Society of Interventional Cardiology, Lisbon

**Lecture:** Clinical applications of OCT

EuroPCR, Paris

**Lecture:** BCIS CTO. Is this an antegrade approach?

**Lecture:** DES and DAPT: Customising treatment duration to your patient

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference Tokyo

**Faculty**

Hybrid CTO Live Case Day, London Chest Hospital, London

**Live Case Operator**

Impella Haemodynamics Course, Rome

**Lecture:** High risk PCI with Impella support

TCT, San Francisco

**Lecture:** OCT after Subintimal intervention

CTO Masters, Belfast

**Live Case Operator**

2014 International Conference on Cell Therapy for Cardiovascular Disease, New York

**Course Co Director**

**Lecture:** CXCR4 Inhibition in STEMI

Chronic Total Occlusion and Left Main Summit, New York

**Lecture:** Antegrade Dissection and Re-Entry

Iran/UK Interventional Cardiology, Cyprus

**Lecture:** Intervention in Acute Myocardial Infarction

European Medicines Agency: Workshop Cell based Cardiac Repair, London

**Lecture:** Expanded Cell Based Medicinal Products: MSCs and Cardiac stem cells

TCT Russia, Moscow

**Lecture:** Healing with biodegradable Polymers

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Antiplatelet Agents in STEMI. Which one and for how long?

**Lecture:** OCT after subintimal angioplasty

Cardiovascular Research Foundation, BVS Summit, Boston

**Lecture:** Importance of Adequate Lesion Preparation for BVS in Calcified and Non Calcified Lesions

**Lecture:** Recoil with BRS: Theoretical or Real Problem

Transcatheter Cardiovascular Therapeutics, San Francisco

**Lecture:** Tips, Tricks and Pearls to Optimize BRS Outcomes From Lesion Preparation to Optimal Pharmacotherapy

BCIS Autumn Meeting, Blackpool

**Lecture:** What's new in CTO Treatment?

Advanced BVS Symposium, Cambridge

**Lecture:** What have we learned so far? Imaging considerations.

Complex PCI Forum, Istanbul

**Course Director**

**Lecture:** Healing with Confidence

**Lecture:** Offering Total Access, Bridgepoint Hybrid Approach

Stenting in Complex PCI, Milan

**Lecture:** CTO and Complete Revascularisation

Gulf PCR, Dubai

**Lecture:** The Integration of FFR and OCT in Daily Practice

2015 4TS Conference, Dubai

**Lecture:** OCT Clinical Applications

American College of Cardiology, San Diego

**Faculty:** CHIP: Complex and Higher Risk Indicated Patients

EuroPCR, Paris

**Lecture:** FFR, OCT, angiography: The benefits of integration into daily practice

CTO Fundamentals Live, Glasgow

**Faculty**

Complex PCI Forum, Bangkok

**Course Director**

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Device and Stent Guideline Reverse CART

Chinese Society of Cardiology and Oriental Society of Cardiology, Shanghai

**Lecture:** BRS: The Fourth Revolution

**Lecture:** Complex PCI and CTO - The UK Experience

**Live Case Operator:** Rui Jin Hospital

Transcatheter Cardiovascular Therapeutics, San Francisco

**Associate Director**

**Scientific Committee**

**Lecture:** What has the development of a CTO Program meant to our institution

**Lecture:** LV to Aorta Pumping : Impella

**Lecture:** Latest innovations in ECMO and Escalation of Therapy

**Lecture:** Why did I adopt OCT

Gulf PCR, Dubai

**Lecture:** Physiological Assessment and the Growing Role of OCT

**Lecture:** PCI Optimisation: Better Outcomes When Using OCT and FFR

**Lecture:** Heartmate PHP

2016 Cardiovascular Centre CTO and Complex PCI Workshop, Sapporo

**Course Director**

**Live Case Operator**

Advanced Haemodynamic Course, Berlin  
**Lecture:** Complete Revascularisation and CTO

Absorb BVS and OCT Symposium, Helsinki  
**Lecture:** Which Patients would Benefit most from BVS

Transcatheter Cardiovascular Therapeutics, San Francisco  
**Associate Director**  
**Late Breaking Trials Committee**  
**Lecture:** Building the CHIP Heart Team  
**Lecture:** OCT was crucial in implanting BRS  
**Webcast:** The Emergence of CHIP angioplasty

CoRe Complete Revascularisation, King's College Hospital  
**Course Director**

CoRe Complete Revascularisation- Zhongshan Hospital Shanghai  
**Course Director**

SCAI Master the Complex Forum, Dubai  
Course Director  
**Lecture:** Healing with biodegradable polymers

Angio OCT CoRegistration Centre of Excellence, London  
**Course Director**  
**Lecture:** OCT for BVS Implantation  
**Lecture:** Precision guided stenting using OCT a systematic stepwise approach

CTO Face to Face Training, Paris  
**Course Director**

2017 Advanced Cardiovascular Intervention, London  
**Lecture:** Intravascular Lithotripsy for Calcified Coronary Artery Disease  
**Lecture:** Use of COMET FFR in complex coronary disease  
**Lecture:** Patient Identification for Protected PCI with Impella

Cardiovascular Centre CTO and Complex PCI Workshop, Sapporo  
**Course Director**  
**Live Case Operator**

Joint Interventional Meeting, Milan  
**Lecture:** Hemodynamic Support for complete revascularisation for CTO

CTO, New York  
**Lecture:** OCT in Complex Coronary Disease and CTO

CoRe Complete Revascularisation, London-Amsterdam  
**Course Director**  
**Live Case Operator**

Chinese Interventional Therapeutics, Beijing  
**Lecture:** Building the CHIP Heart Team: Institutional and Network Strategies for a successful CHIP Program  
**Lecture:** BVS Implantation Algorithm Using AngioOCT CoRegistration  
**Lecture:** Tips and Tricks of Bridgepoint Devices: Crossbos and Stingray  
**Lecture:** Use of OCT during BRS Implantation  
**Live Case Operator, Anzhen Hospital**

Intravascular Coronary Imaging and Physiology Workshop, New York  
**Lecture:** OCT in Complex Coronary Disease

AMEA Complex PCI Symposium, Hong Kong

**Course Director**

**Lecture:** The Evolution of PCI

Angio Co-Registered OCT to Guide PCI Procedures, Kings' College Hospital

**Course Director**

**Live Case Operator**

Multi-Level CTO Course, Nice

**Lecture:** Toolbox for Effective Dissection Re-Entry Techniques

**Lecture:** When you cannot cross the proximal cap with a microcatheter

**Live Case Operator**

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Treating tandem lesions & diffuse disease: FFR iFR & CoRegistration

**Lecture:** Antegrade Dissection and Re-Entry

**Lecture:** OCT guided complex PCI

ENCORE Endovascular & Coronary Revascularisation, Seoul

**Lecture:** Bioabsorbable Stents: Hype or hope

Transcatheter Cardiovascular Therapeutics, Denver

**Faculty**

Heart Live, Manchester

**Live Case Operator**

2018 Taiwan Society of Cardiovascular Interventions, Taiwan

**Lecture:** Antegrade Dissection Re-Entry

**Live Case Operator**

Massy Hospital, Paris

**Live Case Proctoring**

Chinese Interventional Therapeutics, Suzhou

**Faculty**

**Live Case Operator**

Optimal CTO, Madrid

**Course Co-Director**

**Live case operator**

TOPIC Tokyo Percutaneous Cardiovascular Intervention Conference, Tokyo

**Lecture:** Current Status of CTO PCI in UK

**Lecture:** Antegrade Dissection and Re-Entry

**Lecture:** OCT guided complex PCI

Transcatheter Cardiovascular Therapeutics, San Diego

**Faculty**

Bern University Hospital

**Live Case Proctoring**

ACTOS, Amsterdam CTO Summit

**Live Case Operator**

CTO Masters Training

**Course Director**

**Live Case Proctoring**

CTO Summit, Guangzhou, China  
**Live Case Proctor**  
**Live Case Operator**

2019 Cardiovascular Research Foundation, New York  
**Webcast: Shockwave Roundtable**

CTO Summit New York,  
**Lecture: Intravascular Imaging for CTOs**

Washington, CRT  
**Faculty**

OCT and Physiology Symposium, CRF and St Francis Hospital, New York  
**Faculty**

CoRe Complete Revascularisation, Royal College Physicians  
**Course Director**  
**Live Case Operator**

CIT, Chinese Interventional Therapeutics  
**Faculty**  
**Live Case Operator**

## Academic Advisory Boards

Year **Organisation/Board**

2005 Cardiovascular Research Foundation, New York  
 Cell Therapy Trial Development: SELECT AMI

2010 Duke Clinical Research Institute, Aldagen  
 Phase 2 Clinical Study Development

European Society of Cardiology, London  
 Task Force on Stem Cell Regeneration of the Heart

2017 NICE  
 UK Working Group on Percutaneous Hemodynamic Support

## Commercial Advisory Boards

Miltenyi Biotech	Cardiovascular Cell Therapy
Orbus Neich	Endothelial progenitor cells
Biologics Delivery Systems	Endomyocardial cell therapy
Genzyme/MG Biotherapeutics	Genetically modified stem cell therapy
Aldagen	Bone marrow mononuclear cell therapy
The Medicines Company	High bleeding risk patients
Medtronic	Coronary Advisory Board
Boston Scientific	Complex PCI, CTO and Intravascular Imaging
Abbott Vascular	Global Innovators' group
Neovasc	Coronary Sinus Reducer
St Jude	OCT Technical Advisory Board
Abiomed	London Cardiogenic Shock Initiative
Shockwave	Intravascular Lithotripsy